Author's posts
One election outcome health system CEOs can agree on
The absence of meaningful healthcare policy through the 2024 election marks a lost opportunity and even more lost time for health system leaders.
One election outcome health system CEOs can agree on
The absence of meaningful healthcare policy through the 2024 election marks a lost opportunity and even more lost time for health system leaders.
First US case of mpox strain reported in California
The California Department of Public Health has confirmed the first known case of Clade I mpox in the U.S., following laboratory testing of a patient who recently traveled from East Africa.
First US case of mpox strain reported in California
The California Department of Public Health has confirmed the first known case of Clade I mpox in the U.S., following laboratory testing of a patient who recently traveled from East Africa.
Florida medical group lays off 47 after filing for bankruptcy
Bradenton, Fla.-based MCR Health, a nonprofit medical group, has filed several WARN notices to lay off a total of 47 employees after it sought Chapter 11 protection Nov. 11.
Florida medical group lays off 47 after filing for bankruptcy
Bradenton, Fla.-based MCR Health, a nonprofit medical group, has filed several WARN notices to lay off a total of 47 employees after it sought Chapter 11 protection Nov. 11.
NYU Langone improves annual operating margin to 3%
New York City-based NYU Langone reported an operating income of $431.4 million (3% margin) for the fiscal year ending Aug. 31, compared with a $358.8 million gain (2.9% margin) in fiscal 2023, according to financial documents published Nov. 18.
NYU Langone improves annual operating margin to 3%
New York City-based NYU Langone reported an operating income of $431.4 million (3% margin) for the fiscal year ending Aug. 31, compared with a $358.8 million gain (2.9% margin) in fiscal 2023, according to financial documents published Nov. 18.
Drugmakers' 340B rebate fight, explained
Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.
Drugmakers' 340B rebate fight, explained
Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.
